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Background: Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard
chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the
adjuvant treatment of malignancies to eradicate or control residual disease. Cytokine-induced killer (CIK) cells are a
heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted
cytolytic activities against tumor cells. Clinical studies have confirmed benefit and safety of CIK cell-based therapy
for patients with malignancies. This clinical trial was conducted to evaluate efficacy and safety of genetically
modified dendritic cells in combination with Cytokine-Induced Killer Cell (gmDCs-CIK) treatment of patients with RCC.
Methods: 28 patients with advanced renal cancer were admitted to Affiliated Hospital of Academy of Military Medical
Sciences from December 2010 to March 2012 and treated by gmDCs-CIK. Clinical efficacy and safety between pre- and
post-treatment were compared.
Results: This analysis showed an objective response rate (ORR) of 39% and a disease control rate (DCR) of as 75%.
There is no significant relationship between clinical efficacy and whether metastasis occurred or not (P > 0.05). There is
no significant relationship between ORR and cycles of treatment (P > 0.05), but DCR was significantly related with
cycles of treatment (P < 0.05). No clinically significant side effects were observed. There were no significant changes of
T cell subsets including CD3+, CD4+, CD8+, CD4+ CD25+ Treg cells except Th1 in peripheral blood between day 30 after
immunotherapy and 1 day before immunotherapy in 11 patients.
Conclusion: DC-CIK is feasible and effective in treating advanced renal cancer and thus provides a new approach.
Trial registration: ClinicalTrials.gov Identifier: NCT01924156. Registration date: August 14, 2013.
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Renal cell carcinoma (RCC) accounts for about [1] 5% of
all new cancer cases worldwide. It is estimated that 27,
0000 new cases will be diagnosed with renal cancer in the
world [2] and its incidence is rising each year. Radical
nephrectomy can be curative for early stage disease, but for
those patients with distant metastases the prognosis is
poor. After complete resection of the primary tumor, recur-
rence develops in another 30% of patients [3]. RCC re-
mains a therapeutic challenge because of its resistance to* Correspondence: chenhu217@yahoo.com.cn
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reproduction in any medium, provided the orconventional therapies such as radiation, chemotherapy,
and hormonal therapy. Although immunotherapy using
interleukin-2 (IL-2) or interferon-alpha (IFN-α) [4] has be-
come an accepted standard treatment for patients with
RCC benefits, it was limited to a minority of patients.
Therefore, attempts to develop more effective and nontoxic
therapeutic strategies are needed. Dendritic cells (DCs) are
professional antigen-presenting cells, as they are endowed
with the unique potential to activate anti-tumor effector T
and B lymphocytes [5]. They have been applied in clinics.
The first study using DC vaccination for patients with RCC
was published in 1999 and altogether 225 clinical trials
have been published so far. Cytokine-induced killer (CIK)
cells, which are non-major histocompatibility complextd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the body’s natural ability to eliminate tumor cells by stimu-
lating and restoring the immune system to recognize and
kill tumor cells. The first clinical study applying autologous
CIK cells for cancer therapy was performed by Schmidt-
Wolf and colleagues in 1999 [6].
Recently, clinical trials were performed aiming at com-
bining active immune therapy using tumor vaccines with
passive immunotherapy using CIK cells [7]. Evidence is
rising that the application of CIK cells in combination
with pulsed DC may indeed improve the immune re-
sponse towards cancer. To improve therapeutic potency
of CIK cells by vaccination, Sun et al. made use of DCs in
combination with CIK cells for the treatment of relapsed
or refractory non-Hodgkin’s lymphoma (NHL) [8]. After
immunotherapy, the CD3+CD8+:CD3+ CD56+ T cell ratio
was improved and IFN-gamma and IL-12 levels were
higher in patients of the DCs–CIK group compared to the
CIK group. Tumor volume was substantially decreased.
Except of transient fever and chill, no remarkable adverse
events happened during or after the treatment. Although
a small number of patients were treated, data imply that
DCs in combination with CIK cells exhibit an improved
anti-tumor immune response.
In this study, we evaluated the efficacy and safety of




The study protocol was approved by the Institutional
Review Board of the Affiliated Hospital of Academy of
Military Medical Sciences. Patients were informed of
the investigative nature of this study, and written con-
sent in accordance with institutional regulations was
obtained prior to study entry. Eligibility criteria were
histopathologically confirmed diagnosis of advanced
renal cancer (stageIIIB-IV), age more than 18 years,
performance status less than 2 [9] and expected sur-
vival duration of more than 3 months; Exclusion cri-
teria were a history of autoimmune disease, evidence of
active infection, seropositivity for HIV or hepatitis B
surface antigen, use of immunosuppressive agents, or
pregnancy. Patients were also excluded if chemotherapy
or immunomodulatory treatment had been conducted
during the previous 4 weeks.
Generation of DCs and CIK cells
DCs Vaccine preparation
Peripheral blood mononuclear cells (PBMC) were isolated
by Ficoll-Paque (PAN Biotech, Aidenbach, Germany)
density gradient centrifugation that were seeded in
75 cm3 culture flasks at a density of 5 ×106 cells/ml for
2 hours at 37°C in RPMI 1640 medium (Biowhittaker,Verviers, Belgium). After 2 hours, the non-adherent
cells were removed for the purpose of CIK culturing
while adherent mono-cytes were cultured for DCs in
RPMI 1640 supplemented with 1000 units/ml granulo-
cyte macrophage colony-stimulating factor (GM-CSF;
Novartis, New Jersey, USA) and interleukin-4 (IL-4)
500 U/ml (Strathmann Biotech, Hannover, Germany)
for 6 days. On day 4, DCs maturation could be achieved
by adding 100 ng/ml tumor necrosis factor-α (TNF-α)
(R&D Systems, Minneapolis, MN,USA); On day 6, DCs
were pulsed with RNA encoding antigen muc-1 and
survivin. On day 7, DCs were harvested, washed, and
suspended again to a final concentration of 1–9 × 107
cells/ml in saline solution for injection.Generation of CIK
Non-adherent cells were prepared in CIK medium
(RPMI 1640 medium containing 500 U/ml rhIL-2 and
100 ng/ml IFN-γ (Hofman La Roche), 50 ng/ml Anti-
CD3 (e-Bioscience) at the density (3–5) × 106/ml, and
then were seeded in 2 L culture bag. Cells were incu-
bated in a humidified atmosphere of 5% CO2 at 37°C.
CIK medium was changed or added according to the
proliferation. CIK cells were harvested on day 11 and 13.Phenotypic analysis
The phenotype of DCs and CIK was determined by flow
cytometry using a FACSCalibur (Becton Dikinson, San
Jose, CA, USA). Cell staining was performed using FITC-
or PE-conjugated mouse antibodies against CD80+, CD86+,
MHCII, CD83+ and CD14+ (Immunotech, Westbrook,
ME, USA) for DCs, as well as CD3+, CD4+, CD8+CD56+
(PharMingen, San Diego, CA, USA) for CIK. For staining,
1 × 105 DCs or CIK cells were suspended in 100 μl of PBS
and were incubated with 10 μl of the antibodies for
30 minutes at 4°C.Immunization protocol
Patients received four subcutaneous injections of 2-5 × 107
cells of Gene-Modified DCs at groin, axilla and neck on
days 7, 9, 11, and 13 respectively; patients received i.v.
infusion of 2-5 × 1010 CIK on both days 11 and 13. IL-2
(2 million IU/m2) was administered every other day during
2-weeks interval. Each cycle of immunotherapy consisted
of 4 injections of DCs and 2 injections of CIK.Evaluation of T lymphocytes subset
For evaluation of the immune status of RCC patients,
CD3+, CD4+, CD8+, CD4+/CD8+ ratio, CD4+ CD25+Treg
cells and Th1/Th2 cell were determined by FCM from
peripheral blood 1 days before immunotherapy and on
day 30 after immunotherapy.
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The primary objective of the study is to determine the
feasibility and safety of gmDCs-CIK cell treatment in
RCC. The secondary endpoints were the overall response
rate (ORR) and disease control rate (DCR). Patients were
assessed serially using computed tomography of chest, ab-
domen and technetium bone scan. Clinical responses to
vaccination were evaluated according to the World Health
Organization criteria. Complete response (CR) was de-
fined as complete disappearance of all clinically detectable
disease. Partial response (PR) was defined as ≥ 50% de-
crease in the sum of the products of the two longest per-
pendicular diameters of all measurable lesions without the
appearance of new lesions. Stable disease (SD) was defined
as 25% increase or 50% decrease in tumor size. Progressive
disease (PD) was defined as ≥25% increase in existing le-
sions or the appearance of a new metastasis.
Advert effects
Toxicities were graded according to National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version 2.0).
Statistical methods
Relationship between metastatic status and ORR/DCR
as well as treatment cycles and ORR/DCR were evalu-
ated with Fisher’s exact test. Th1/Th2 and T cell subsets
were analyzed with either paired-t tests or nonparamet-
ric Wilcoxon signed-rank tests based upon the normality
of data. A value of p < 0.05 was considered significant.
The SPSS 16.0 software package (SPSS, Inc.) was used.
Results
Patient characteristics and phenotypic analysis
From December 2010 through March 2012, 28 patients
(mean age: 51.5 years; 23 men and 5 women) with meta-
static RCC with clear cell histology were enrolled, with all
of them had an ECOG performance status smaller than 1
upon initial screening. Of these patients, thirteen patients
received one cycle of immunotherapy, seven received two
cycles, five received three cycles, and two received four cy-
cles. Demographics are summarized in Table 1.
The mature DCs phenotype was reflected by a mean per-
cent positive value of 5.7 ± 10.0 for monocyte marker
CD14+, 60.4 ± 23.7% for DC marker CD83+, and 90.8 ±
13.0%, 83.2 ± 22.6%, and 81.7 ± 13.6% for MHCII, CD80+,
and CD86+, respectively. Phenotypic analysis of CIK cells
in 28 patients and after 11 days of culture showed that per-
centages of CD3+, CD3+CD4+, CD3+CD8+, CD3+CD56+
cell subsets is 82.06% ± 9.21%, 43.70% ± 6.08%, 36.31 ±
5.16%, and 18.24% ± 4.71%, respectively.
Immunologic responses to gmDCs-CIK
Peripheral blood lymphocyte subset proportions were
measured using flow cytometry. The percentage of CD3+,CD3+CD4+, CD3+CD8+, CD16+CD56+ and CD4+CD25+
treg cell and CD4+/CD8+T cell ratio did not differ sig-
nificantly between 1 day before immunotherapy and
day 30 after immunotherapy (P > 0.05). There is signifi-
cant difference for Th1 but not for Th2 (Figure 1) by
flow cytometry.
Clinical outcomes and safety
Among all those 28 patients who were available for clin-
ical assessment, there are 4 CR with 2 of them more
than 10 months and the other 2 more than 15 months, 7
PR (6.0-21.0 months), and 10 SD (5.0-21.0 months), 6
PD, and 1 death. ORR is 39% and DCR 75%. Follow-up
ranges from 4 to 21 months.
During the immunotherapy, no adverse events with
grade greater than 2 were reported. Patients with only
flu-like symptoms with fever were noticed but didn’t re-
quire additional treatment (shown in Table 1).
Association of ORR/DCR with other variables
Significant correlations were not found between ORR/
DCR and metastatic site (p > 0.05) (Table 2). However,
for patients with metastasis especially from lung site,
there was great reduction in tumor size after immuno-
therapy (Figure 2). Correlations were not found between
ORR and cycles of treatment, whereas correlations were
found between DCR and cycles of treatment (i.e. 1 cycle
vs. more than 1 cycle) (Table 3).
Discussion
Treatment of RCC, especially metastatic RCCs, confronts
a great dilemma in clinical practice. Although there are a
number of therapeutic options available such as the
immuno-regulating cytokines and the new anti-angiogenic
targeted agents at present, these are commonly toxic and
rarely produce durable complete remissions. The recent
considerable success of cell immunotherapy in melanoma
warrants further efforts to apply this treatment to other
cancers including RCC.
Based on the antigen specificity of the immune system
and the safety profile of cancer vaccines, the effective
immunotherapy would be an ideal adjuvant, following
initial clinical responses to definitive therapy [10]. In
2010, Yang B conducted autologous cytokine induced
killer cells combined with IL-2 for therapy of elderly
patients with B-cell malignant lymphoma [11]. The re-
sults showed that no adverse reaction was observed in
all above mentioned patients. The percentages of CD3+,
CD3+CD8+ and CD3+CD56+ increased significantly (p < 0.05),
and serum levels of β2-microglobulin and LDH were
markedly decreased (p < 0.05) after autologous CIK cell
transfusion. The lymphoma symptoms were relieved
with quality of life obviously elevated (p < 0.01) in all


































Figure 1 The changes of Th1/Th2 after treatment for 11 patients.
Table 1 Patient characteristics and response














01 F CC Liver 1 PD PD Sunitinib No 20 m+
02 M CC Lung, bone 1 PD PD None No 20 m+
03 M CC Lung, bone 1 PD PR None No 20 m+
04 M CC Lung, bone 2 PD SD None No 19 m+
05 M CC Lung, Liver 6 SD PR None No 19 m+
06 M CC Bone 4 PD SD None No 18 m+
07 M CC Bone 1 PD SD None No 17 m+
08 M CC Lung 4 SD PR None No 18 m+
09 M CC Lung, Liver, Brain 2 PD SD None No 21 m+
10 M CC Chest 3 PD SD None No 16 m+
11 M CC Lung 1 PD PR None No 16 m+
12 M CC Liver 1 PD PD None Fever (grade1) 15 m+
13 M CC Neck lymph 1 PD CR None No 10 m+
14 M CC Lung 1 PD SD None No 10 m+
15 M CC Lung 3 PD PR None No 9 m+
16 M CC Lung 3 PD CR None No 10 m+
17 M CC Abdominal 1 PD CR None No 15 m+
18 M CC Lung 1 PD PD None No 12 m+
19 M CC peritoneum lymph 1 SD PR None No 21 m+
20 F CC Liver, Bone 1 PD PD None No 15 m+
21 F CC Abdominal 2 PD PD None No 16 m+
22 M CC Bone 2 SD CR sorafenib No 20 m+
23 M CC Lung, Bone 3 SD SD None No 6 m+
24 F CC Lung, Bone 1 PD death None No 4 m+
25 M CC Lung, Liver 3 PD PR Sorafenib + Sunitinib No 6 m+
26 F CC Peritoneum lymph 2 SD SD None No 11 m+
27 M CC Lung, Bone 2 PD SD None No 5 m+
28 M CC Lung 2 SD SD sorafenib No 5 m+
Abbreviations: PT patient, VAX vaccination, M male, CC renal clear cell carcinoma, F female, SD stable disease, CR completed response, PR partial response,
PD progression of disease.
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safe and effective for the therapy of elderly patients with
B-cell malignant lymphoma. In 2009, Thomas Schwaab
and colleagues made use of autologous dendritic Cell with
IL-2 therapy in RCC Patients [12]. The results showed all







Sig. (2-sided)Effective No effect
1 5 8 13 38.5
1.000≥2 6 9 15 40
Totle 11 17 28 39.3
A B
Figure 2 Clinical response to gmDCs-CIK treatment patient with renal cancer. CT scans of patient with renal cancer showing lung metastases.
(A) arrow, sites are from lung metastases before gmDCs-CIK treatment, (B) arrow, sites are from lung metastases after gmDCs-CIK treatment.
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complete responses. Treatment-related changes in cor-
relative immunologic end points were noted.
On the basis of above research reports, we propose a
new combinatorial therapy approach to mobilize anti-
tumor immunity against RCC. Our results indicate that
vaccination of these patients with gmDCs-CIK is safe
and efficient. We found a ORR (39%) and a CRR (12%)
which compared favorably to the historical observations
of ORR (16%) and CR (6%) for high-dose IL-2 or IL-2
plus IFN-α therapy [13-16]. In addition, Turnbull JD and
his colleages had reported results of a clinical trial [17]
of bevacizumab in treating mRCC showing an ORR of
9.5% which was not superior to ORR in our study.
Moreover, data of DCR is superior to other related clin-
ical research [18,19]. For example, Kadono Y et al. had
conducted a clinical trial of IFN-α in systemic treatment
on 15 patients with mRCC enrolled from June 2005
through September 2008 [20] showing an ORR of 7%
and a DCR of 27% which is lower than our DCR of 75%.
Clinical response of immunotherapy was evaluated by
WHO and RESIST in a large number of clinical trial.
However there is now ample evidence that these criteria
do not apply to immunotherapy [21]. Immunotherapy in-
duced tumor regressions have been well documented after
initial progression and even after the appearance of new
lesions, which are presumably caused by the infiltration of







Sig. (2-sided)Effective No effect
1 7 6 13 53.8
0.029*≥2 14 1 15 93.3
Total 21 7 28 75
*P value less than 0.05 indicates statistical significance.receiving ipilimumab, metastases may grow or new lesions
may even develop before there is a decline in total tumor
burden. These observations have led to the proposal of
novel immune-related response criteria, as response
evaluation according conventional response criteria (such
as WHO and RECIST) can lead to unwanted early cessa-
tion of treatment owing to initial tumor growth [22].
These observations reflect the different dynamics of the
immune response compared with the direct effects of
cytotoxic drugs on cancer cells [23]. This also has import-
ant implications for the design and conduct of clinical tri-
als, such as the planning of interim analyses.
Historically, cancer immune therapies have focused on
stimulation of effector cells. In the present study, we ob-
served no obvious difference between pre-vaccination
and post-vaccination in Th2 but Th1 is significant higher
than pre-vaccination (p = 0.003). Subsets of lymphocyte
were evaluated in 11 patients with RCC treated with
gmDCs-CIK. Result shows CD3+, CD4+, CD4+/CD8+,
CD56+, CD4+CD25+doesn’t have significantly difference
(P > 0.05) as compared with treatment before. Th cells
are central to the development of an immune response
by activating antigen-specific effector cells and recruiting
cells of the innate immune system [24]. Two predomin-
ant Th cell subtypes exist, Th1 and Th2. Th1 cells, char-
acterized by secretion of IFN-gamma and TNF-alpha,
are primarily responsible for activating and regulating
the development and persistence of CTL. In addition,
Th1 cells activate antigen-presenting cells (APC) and in-
duce limited production of the type of antibodies that
can enhance the uptake of infected cells or tumor cells
into APC. Th2 cells favor a predominantly humoral re-
sponse. Th1 immune response is considered more effect-
ive than T helper 2 (Th2) for anti-tumor immunity. In
this study, Th1 is significant higher than pre-vaccination
by immunotherapy which indirectly proves that the im-
munological effect. Most data on lymphocyte subsets in
malignant disease originate from melanoma or renal cell
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plying that the relative amount of CD3+, CD4+, CD8+,
and CD56+ may be important and by reducing the
tumor burden. However, only some of these studies
imply that these changes can have an correlation on
clinical outcome and prognosis [21]. Our results showed
no correlation between recent clinical efficacy and meta-
static sites from either bone or lung. This differed from
results from other references for the difference of TNM
staging of renal cancer, time of immune treatment, cycle
of treatment, and time of testing of the peripheral blood
lymphocyte subsets [25]. However, at present there is a
lack of robust assays to monitor the anti-tumor immune
response. Although there is an abundance of different
assays that are being used to measure tumor antigen-
specific T cell responses, these assays have not shown
consistent results among trials, and none has been vali-
dated in prospective clinical trials.Conclusion
In conclusion, genetically modified DCs in combination
with CIK represent a novel immunotherapy approach for
treating advanced RCC. gmDCs-CIK is safe and effective
for RCC. We have revealed, for the first time, the relation-
ship between cycle of treatment and the DCR; our study
also has indicated that immunotherapy could improve the
clinical efficacy of advanced renal cancer and increased
frequency of immunotherapy could result in additional
benefits. A larger scale clinical trial should be conducted
to confirm the conclusion. Standardization of immuno-
therapy needs to be the focus of ongoing research.
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